Celine Biotechnologies develops a scalable platform utilizing human-based data to uncover novel biomarkers and advance immune rejuvenation medicine. The company applies precision AI to address complex age-related diseases, including cancer, inflammation, and neurodegeneration. This data-driven approach aims to restore health and extend human healthspan through early detection.
Funding
Funding not disclosed
Founders
Product
Problem
Age-related diseases represent a significant portion of healthcare expenditure, driven by complex immune system dysregulation. Current therapeutic approaches often lack the multi-dimensional, personalized strategy required to effectively address the intricate biological mechanisms underlying these conditions.
Solution
Celine Bio is developing a tech-bio platform that utilizes large-scale patient data and Generative AI to identify synergistic protein combinations for precision medicine. The platform decodes immune cell dysfunction to reset immune function and extend healthy lifespans. By analyzing complex disease ecosystems and patient variability, Celine Bio aims to unlock novel therapies for age-related diseases such as cancer, inflammation, and neurodegenerative conditions. This approach facilitates the development of next-generation treatments designed to improve patient outcomes.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology firms, and academic research institutions focused on developing novel therapeutics for age-related diseases.
Features
- Generative AI models for identifying synergistic protein combinations from large-scale patient datasets.
- Proprietary platform for decoding immune cell dysfunction and resetting immune function.
- Multi-dimensional analysis of disease ecosystems, incorporating patient diversity and genetic variability.
- Focus on therapeutic development for age-related diseases including oncology, inflammation, and neurodegeneration.
- Data integration pipeline for comprehensive patient data analysis.